What is riluzole?
Riluzole is a glutamate release inhibitor indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS)1,5. Riluzole is a generic form of Rilutek (riluzole).
How does riluzole work?
It is still not clear how ALS develops, however it seems that the neurotransmitter glutamate plays a role in cell death. Riluzole is thought to act by inhibiting the release of glutamate1,2,3,4,5.
Riluzole aims to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). There is no evidence that it has a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms2,3,4,5.
Where has riluzole been approved?
Riluzole was approved for the treatment of patients with ALS by:
Therapeutic Goods Administration (TGA), Australia, February 20165
The Medicines Evaluation Board (MEB), The Netherlands, June 20141.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is riluzole taken?
The standard dosage is1,5:
Complete information about riluzole dosage and administration can be found in the official prescribing information listed in our resources section1,2,3.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of riluzole?
Common adverse reactions
The most common adverse reactions listed in the prescribing information include1:
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include1:
Use in specific populations
Riluzole can be fatal for a fetus, it is advised to avoid pregnancies and breast feeding1.
Riluzole should not be used by patients who have liver disease or increased blood levels of some liver enzymes (transaminases)1.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,5.